相关实验视频
Updated: Mar 10, 2026

16:31
Fixed Volume or Fixed Pressure: A Murine Model of Hemorrhagic Shock
Published on: June 6, 2011
25.7K
重新思考败血性休克时的液体复苏:一个相适应的,节省内皮的方法来缓解毛细血管泄漏
1Department of Intensive Care Unit, The People's Hospital Medical Group of Xiangzhou, Zhuhai, Guangdong, People's Republic of China.
Journal of inflammation research
|March 9, 2026
概括
败血症复苏需要一个个性化的方法,超越了晶体与合体. 这种新的阶段适应,内皮节约 (PAES) 策略将液体复苏定制为败血性休克阶段,优化结果.
科学领域:
- 关键护理医学 关键护理医学
- 血管生物学 血管生物学
- 复苏科学复苏科学 复苏科学
背景情况:
- 败血症引起的内皮功能障碍和毛细血管泄漏综合征复杂化了败血症休克的管理.
- 由于对败血症病理生理学的理解不断发展,传统的液体复苏策略面临挑战.
- 结晶体和体复苏之间的辩论正在转向一种更具生理学依据的方法.
研究的目的:
- 批判性地检查败血症诱导的血管透性的病理生理学.
- 审查在败血症休克中液体复苏范式的演变.
- 提出一种新的,相应的复苏策略 (PAES),以改善患者的治疗结果.
主要方法:
- 叙事综述综合了病理生理学的见解和最近的临床试验证据.
- 批判性地检查流体特性和复苏的限制.
- 拟议的相适应,内皮节约 (PAES) 复苏框架.
主要成果:
- 败血症涉及复杂的内皮功能障碍,包括葡萄糖降解和细胞因子风暴.
- 结晶体主导的协议可能会导致血管内体积耗尽和器官损伤.
- 该PAES策略整合流体类型和体积,基于不同的污水冲击阶段 (救援,优化,稳定,降级).
结论:
- 一个适合所有人的液体复苏策略对于败血症休克已经过时了.
- 该PAES策略倡导最初使用平衡的晶体,在特定子组中使用明智的白蛋白.
- 以血液动力学监测和生物标志物为指导的个性化流体管理可以优化输液并减轻微循环损伤.
相关概念视频
Acute Respiratory Failure-V
578
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
578
Cardiopulmonary Resuscitation IV: Pharmacological Management
1.1K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.1K
Heart Failure VI: Adjunct Therapies
493
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
493

